

Claim 29. Polyclonal antibodies produced against a marker sequence ID including the sequence SEQ ID NO: 1. or an analyte thereof in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker consisting of the sequence SEQ ID NO: 1. or at least one analyte thereof.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer consisting of the sequence SEQ ID NO: 1. or at least one analyte thereof.

Claim 38. A process for regulating a disease state by controlling the presence or absence of a biopolymer selected from the group consisting of the sequence SEQ ID NO: 1. or at least one analyte thereof.

REMARKS

The foregoing Preliminary Amendment is made in conjunction with the simultaneous entry of the response to the Notice to File Missing Parts, filed concurrently herewith, so as to further bring this application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added. Examination on the merits is respectfully requested.